Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
暂无分享,去创建一个
Malcolm Rowland | Alasdair Breckenridge | Bruno Flamion | Eric Abadie | A. Breckenridge | H. Eichler | L. Gustafsson | M. Rowland | E. Abadie | H. Leufkens | B. Flamion | C. Schneider | B. Bloechl-Daum | Hans-Georg Eichler | Lars L. Gustafsson | Hubert Leufkens | Christian K. Schneider | Brigitte Bloechl-Daum | Brigitte Bloechl-Daum
[1] S. Kimmel,et al. Textbook of pharmacoepidemiology , 2013 .
[2] J. Laporte,et al. Topiramate in non-approved indications and acute myopia or angle closure glaucoma. , 2005, British journal of clinical pharmacology.
[3] J. Urquhart. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. , 2002, British journal of clinical pharmacology.
[4] J. Urquhart,et al. Understanding Forgiveness: Minding and Mining the Gaps Between Pharmacokinetics and Therapeutics , 2010, Clinical pharmacology and therapeutics.
[5] J. Ware,et al. Pragmatic trials--guides to better patient care? , 2011, The New England journal of medicine.
[6] J. Woodcock. Assessing the Clinical Utility of Diagnostics Used in Drug Therapy , 2010, Clinical pharmacology and therapeutics.
[7] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[8] C. Wijbrandts,et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. , 2011, Arthritis and rheumatism.
[9] Jonas Larsson,et al. Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region - Bridging the gap between knowledge and practice , 2007, Int. J. Medical Informatics.
[10] W. Jack,et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial , 2010, The Lancet.
[11] George M. Savage,et al. A networked system for self-management of drug therapy and wellness , 2010, Wireless Health.
[12] G. Kéri,et al. Integrating molecular diagnostics into anticancer drug discovery , 2010, Nature Reviews Drug Discovery.
[13] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[14] S. Pocock,et al. More on subgroup analyses in clinical trials. , 2008, The New England journal of medicine.
[15] David M Cutler,et al. Thinking outside the pillbox--medication adherence as a priority for health care reform. , 2010, The New England journal of medicine.
[16] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[17] R. Verbrugge,et al. Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.
[18] P. Hjemdahl,et al. Usage, Risk, and Benefit of Weight-Loss Drugs in Primary Care , 2011, Journal of obesity.
[19] Robert C. Wolpert,et al. A Review of the , 1985 .
[20] W. Harris. Clearing the confusion. , 1991, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[21] L Aarons,et al. Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[22] Mark R. Trusheim,et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.
[23] Bethan Hughes,et al. 2009 FDA drug approvals , 2010, Nature Reviews Drug Discovery.
[24] S. Poole,et al. Off-label prescribing in oncology , 2004, Supportive Care in Cancer.
[25] S. Wedrén,et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. , 2011, Arthritis and rheumatism.
[26] J. Urquhart,et al. The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. , 2005, Basic & clinical pharmacology & toxicology.
[27] P. Donnan,et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study , 2008, Pharmacogenetics and genomics.
[28] C. Viscoli,et al. Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.
[29] D. Bailey. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. , 2010, British journal of clinical pharmacology.
[30] J Urquhart,et al. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. , 1996, European heart journal.
[31] Ian Harvey,et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers , 2009, Canadian Medical Association Journal.
[32] R. Moore,et al. Using Numerical Results from Systematic Reviews in Clinical Practice , 1997, Annals of Internal Medicine.
[33] Michael J. Goodman,et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. , 2000, JAMA.
[34] M. Ingelman-Sundberg. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001, Journal of internal medicine.
[35] R. Stafford,et al. Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.
[36] Tomas Salmonson,et al. New drug approval success rate in Europe in 2009 , 2010, Nature Reviews Drug Discovery.
[37] George Hripcsak,et al. Accelerating the use of electronic health records in physician practices. , 2010, The New England journal of medicine.
[38] Regulatory policies on medicines for psychiatric disorders: is Europe on target? , 2007, British Journal of Psychiatry.
[39] John Urquhart,et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.
[40] Chikayuki Naito,et al. Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .
[41] Carl Peck,et al. Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999 , 2002, Pharmacoepidemiology and drug safety.
[42] W. Evans,et al. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status , 2010, Expert opinion on drug safety.
[43] Els Goetghebeur,et al. Modelling the association between adherence and viral load in HIV‐infected patients , 2005, Statistics in medicine.
[44] L. Kohn,et al. To Err Is Human : Building a Safer Health System , 2007 .
[45] W. Hollingworth,et al. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population , 1996, BMJ.
[46] Geoffrey S Ginsburg,et al. The long and winding road to warfarin pharmacogenetic testing. , 2010, Journal of the American College of Cardiology.
[47] E. Autret‐Leca,et al. Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study , 2005, European Journal of Clinical Pharmacology.
[48] P. Hjemdahl,et al. The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. , 2011, Basic & clinical pharmacology & toxicology.
[49] R. Schilsky. Personalized medicine in oncology: the future is now , 2010, Nature Reviews Drug Discovery.
[50] Efthymios Manolis,et al. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. , 2009, British journal of clinical pharmacology.
[51] Hein Putter,et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] John Urquhart,et al. Changes in prescribed drug doses after market introduction , 2002, Pharmacoepidemiology and drug safety.
[53] Rethinking therapeutic cancer vaccines , 2009, Nature Reviews Drug Discovery.
[54] Uwe Siebert,et al. EBM, HTA, and CER: clearing the confusion. , 2010, The Milbank quarterly.
[55] Marc S. Williams,et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin , 2008, Genetics in Medicine.
[56] L. Gustafsson,et al. Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. , 2010, Basic & clinical pharmacology & toxicology.
[57] B. Chi,et al. Mobile phones to improve HIV treatment adherence , 2010, The Lancet.
[58] P. Bahri. Public Pharmacovigilance Communication , 2010, Drug safety.
[59] Anders Sundström,et al. The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.
[60] F. Kamali,et al. Pharmacogenetics of warfarin. , 2010, Annual review of medicine.
[61] C. Marano,et al. To err is human. Building a safer health system , 2005 .
[62] Tuomas Korhonen,et al. SFINX—a drug-drug interaction database designed for clinical decision support systems , 2009, European Journal of Clinical Pharmacology.
[63] G. Ogedegbe. Self-titration for treatment of uncomplicated hypertension , 2010, The Lancet.
[64] J. Woodcock,et al. The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.
[65] C. Peck,et al. Chronobiology. Suggestions for integrating it into drug development. , 1991, Annals of the New York Academy of Sciences.
[66] Ian Harvey,et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. , 2009, Journal of clinical epidemiology.
[67] S. Friend,et al. An accelerated pathway for targeted cancer therapies , 2011, Nature Reviews Drug Discovery.
[68] P. Rothwell,et al. Factors That Can Affect the External Validity of Randomised Controlled Trials , 2006, PLoS clinical trials.
[69] Walter E Haefeli,et al. e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. , 2012, British journal of clinical pharmacology.
[70] Matthew E Falagas,et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults , 2010, The Lancet.
[71] Alasdair Breckenridge,et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma , 2008, Nature Reviews Drug Discovery.
[72] John Urquhart,et al. Patient adherence to prescribed antimicrobial drug dosing regimens. , 2005, The Journal of antimicrobial chemotherapy.
[73] A. Quittner,et al. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? , 2006, Journal of pediatric psychology.
[74] L. Smeeth,et al. A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example , 2009, PLoS medicine.
[75] David W. Bates,et al. Viewpoint Paper: Evaluation and Certification of Computerized Provider Order Entry Systems , 2007, J. Am. Medical Informatics Assoc..
[76] A Keskinaslan,et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review , 2007, International journal of clinical practice.
[77] David G. Hicks,et al. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. , 2009, The oncologist.
[78] J. Urquhart,et al. Variability in patterns of drug usage. , 1994, The Journal of pharmacy and pharmacology.
[79] Allen D. Roses,et al. Pharmacogenetics in drug discovery and development: a translational perspective , 2008, Nature Reviews Drug Discovery.
[80] B. Falissard,et al. Relative effectiveness assessment of listed drugs (REAL): A new method for an early comparison of the effectiveness of approved health technologies , 2010, International Journal of Technology Assessment in Health Care.
[81] A. Heusch,et al. Off-label drug use among hospitalised children: identifying areas with the highest need for research , 2008, Pharmacy World & Science.
[82] D. Greenblatt. Analysis of Drug Interactions Involving Fruit Beverages and Organic Anion‐Transporting Polypeptides , 2009, Journal of clinical pharmacology.
[83] U. Reinhardt,et al. Perspectives on the pharmaceutical industry. , 2001, Health affairs.
[84] Nick C. Fox,et al. Biomarkers for Alzheimer's disease therapeutic trials , 2011, Progress in Neurobiology.
[85] S. De Geest,et al. Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[86] T. Frieden,et al. Tuberculosis in New York City--turning the tide. , 1995, The New England journal of medicine.
[87] F. Schena,et al. Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients , 2010, Clinical and experimental immunology.
[88] R. Schosser. Risk/Benefit Evaluation of Drugs: The Role of the Pharmaceutical Industry in Germany , 2002, European Surgical Research.
[89] Ma. Louise. Poisoning Associated With Use of LPG-Powered(Propane)ForkliftsinIndustrial Settings—Iowa, 1998 , 2000 .
[90] R. Temple,et al. Enrichment of Clinical Study Populations , 2010, Clinical pharmacology and therapeutics.